Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer

Scott Saxman, Patrick J. Loehrer, Keith Logie, Doyle Stephens, Frank Workman, Daniel Scullin, Lawrence H. Einhorn, Rafat Ansari

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Forty-six previously untreated patients with advanced non-small cell lung cancer (NSCLC) were entered into a Hoosier Oncology Group phase II trial of daily oral etoposide 50 mg/m2/d. The dose limiting toxicity was granulocytopenia. The non-hematologic toxicity was mild, with only 19% of patients developing Grade 3 or 4 leukopenia. Two partial responses of 10 and 16 weeks duration were seen in 43 evaluable patients, for an overall response rate of 4%. We conclude that daily oral etoposide has minimal activity in advanced NSCLC, and does not improve response rates over conventional 1-5 day intravenous etoposide administration.

Original languageEnglish (US)
Pages (from-to)253-256
Number of pages4
JournalInvestigational New Drugs
Volume9
Issue number3
DOIs
StatePublished - Aug 1 1991

Keywords

  • etoposide
  • lung cancer

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this